Al Root
Sometimes growth in one business can't overcome declines in another.
Thursday evening, chemical maker Chemours reported adjusted third-quarter earnings of 20 cents a share from sales of $1.5 billion. Wall Street was looking for 25 cents a share and $1.5 billion, respectively.
Chemours' stock was off 8.4% in early trading Friday, while the S&P 500 and Dow Jones Industrial Average were off 0.6% and 0.2%, respectively. Coming into Friday trading, Chemours' shares were down 31% year to date.
Earnings were light, driven by slowing sales of titanium dioxide, a key component of white paint. The titanium segment's sales fell 9% from a year earlier to $612 million, and pricing was down 8%, according to the company.
Refrigerant sales were a standout at $560 million, up 20% year over year. "Volume growth was driven by stronger demand for Opteon...in connection with the stationary air conditioning.... transition under the U.S. AIM Act," said the company.
The AIM Act is designed to reduce the use of hydrofluorocarbon-based refrigerants. Opteon is hydrofluoroolefin-based. It's an HFO, not an HFC, and has a lower propensity to heat up the planet when released into the atmosphere.
The fourth-quarter outlook was also light. Management expects sales to drop 10% to 15% year over year, implying revenue of about $1.2 billion. Analysts are projecting $1.4 billion.
"We expect Opteon to drive the majority of sales in Q4 [the fourth quarter] and 2026," wrote CFRA analyst Emily Nasseff Mitsch in a Thursday report, "while other segments face continued pressure from lower volumes and weak pricing dynamics."
She rates shares Sell and has an $11 price target for the stock. Truist analyst Pete Osterland rates shares Buy and has a $21 price target for the stock. He acknowledged the problem of titanium dioxide weakness in his post-earnings report, but remains optimistic about the growth of the company's refrigerant business.
Overall, 55% of analysts covering the stock rate shares Buy, according to FactSet. The average Buy-rating ratio for stocks in the S&P 500 is about 55%. The average analyst price target is about $17.50 a share.
Write to Al Root at allen.root@dowjones.com
This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
November 07, 2025 11:33 ET (16:33 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.